GeneQuine Biotherapeutics is Developing Disease-Modifying Treatment for Osteoarthritis and Degenerative Disc Disease

by Kathleen Crosby | June 1, 2021

People,Medicine,Medical Supplies,Healthcare And Medicine,Vertical,Rear View,Back,Body Part,Torso,Waist,Caucasian Ethnicity,Illness,Medical Condition,Massaging,Holding,Stretching,Number of People,Adult,Pain,Backache,Physical Injury,Cut Out,Cramp,Males,Human Gender,Men,Only Men,One Man Only,Photography,White Background,White Color,Adults Only,Human Back

At last month’s Biotech Start-up Symposium, Killian Guse of GeneQuine Biotherapeutics spoke about their next generation gene therapy for musculoskeletal disorders. Gene therapy is currently a hot field in drug development, and large pharma companies are buying into it.

While gene therapy was first developed and utilized for orphan diseases, GeneQuine is looking into its uses in larger, more mainstream illnesses including osteoarthritis and degenerative disc disease. There are currently no disease-modifying drugs available for these conditions, and they come at a cost of billions of dollars a year for treatments.

Over 77 million people in the US and Europe are affected by lower back pain, and back pain is a top cause for years lived with disability for all developed nations. 3.5 million new patients are diagnosed with degenerative disc disease every year, and GeneQuine has developed a single, intradiscal injection that modifies the disease, rather than just treating the symptoms.

In this treatment, therapeutic proteins are injected directly into the affected joints (osteoarthritis) or between affected vertebrae (degenerative disc disease). This is a game changer in the back pain field because just one injection leads to symptom relief, healing, and a better quality of life.

Related Posts

Hiring Challenges in Bioprocessing for Start-ups

Creating Bottlenecks in Europe; Opportunities for Production Staff BioPlan Associates, Inc. Hiring of bioprocessing professionals has remained a…

When to sprint and when to breathe in the race from lab to clinic – 5 critical steps to success

As an early-stage or small-sized biotech company, you need to move fast and be nimble.  Success is measured…

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

A Streamlined Approach to Analytical Method Development and Implementation

The development and implementation of analytical methods are essential for success at all phases of a molecule’s journey,…

Scroll to Top